Ataxin-2: a Powerful RNA-binding Protein

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jul 22

PMID 39039334

Authors

Lulu Li

Meng Wang

Lai Huang

Xiaoli Zheng

Lina Wang

Hongming Miao

Affiliations

Soon will be listed here.

Abstract

Ataxin-2 (ATXN2) was originally discovered in the context of spinocerebellar ataxia type 2 (SCA2), but it has become a key player in various neurodegenerative diseases. This review delves into the multifaceted roles of ATXN2 in human diseases, revealing its diverse molecular and cellular pathways. The impact of ATXN2 on diseases extends beyond functional outcomes; it mainly interacts with various RNA-binding proteins (RBPs) to regulate different stages of post-transcriptional gene expression in diseases. With the progress of research, ATXN2 has also been found to play an important role in the development of various cancers, including breast cancer, gastric cancer, pancreatic cancer, colon cancer, and esophageal cancer. This comprehensive exploration underscores the crucial role of ATXN2 in the pathogenesis of diseases and warrants further investigation by the scientific community. By reviewing the latest discoveries on the regulatory functions of ATXN2 in diseases, this article helps us understand the complex molecular mechanisms of a series of human diseases related to this intriguing protein.

Citing Articles

The LSmAD Domain of Ataxin-2 Modulates the Structure and RNA Binding of Its Preceding LSm Domain.

Zhang S, Zhang Y, Chen T, Hu H, Lu C Cells. 2025; 14(5).

PMID: 40072111 PMC: 11898529. DOI: 10.3390/cells14050383.

References

Henden L, Fearnley L, Grima N, McCann E, Dobson-Stone C, Fitzpatrick L . Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia. Sci Adv. 2023; 9(18):eade2044. PMC: 10162670. DOI: 10.1126/sciadv.ade2044. View

Chintalaphani S, Pineda S, Deveson I, Kumar K . An update on the neurological short tandem repeat expansion disorders and the emergence of long-read sequencing diagnostics. Acta Neuropathol Commun. 2021; 9(1):98. PMC: 8145836. DOI: 10.1186/s40478-021-01201-x. View

DeJesus-Hernandez M, Mackenzie I, Boeve B, Boxer A, Baker M, Rutherford N . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72(2):245-56. PMC: 3202986. DOI: 10.1016/j.neuron.2011.09.011. View

Elden A, Kim H, Hart M, Chen-Plotkin A, Johnson B, Fang X . Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466(7310):1069-75. PMC: 2965417. DOI: 10.1038/nature09320. View

Lattante S, Pomponi M, Conte A, Marangi G, Bisogni G, Patanella A . ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. Neurobiol Aging. 2017; 64:157.e1-157.e5. DOI: 10.1016/j.neurobiolaging.2017.11.011. View

Abramzon Y, Fratta P, Traynor B, Chia R . The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci. 2020; 14:42. PMC: 7012787. DOI: 10.3389/fnins.2020.00042. View

Lastres-Becker I, Rub U, Auburger G . Spinocerebellar ataxia 2 (SCA2). Cerebellum. 2008; 7(2):115-24. DOI: 10.1007/s12311-008-0019-y. View

Albrecht M, Golatta M, Wullner U, Lengauer T . Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem. 2004; 271(15):3155-70. DOI: 10.1111/j.1432-1033.2004.04245.x. View

Laffita-Mesa J, Velazquez-Perez L, Santos Falcon N, Cruz-Marino T, Gonzalez Zaldivar Y, Vazquez Mojena Y . Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Hum Genet. 2011; 20(1):41-9. PMC: 3234519. DOI: 10.1038/ejhg.2011.154. View

10.

Yokoshi M, Li Q, Yamamoto M, Okada H, Suzuki Y, Kawahara Y . Direct binding of Ataxin-2 to distinct elements in 3' UTRs promotes mRNA stability and protein expression. Mol Cell. 2014; 55(2):186-98. DOI: 10.1016/j.molcel.2014.05.022. View

11.

Ciura S, Sellier C, Campanari M, Charlet-Berguerand N, Kabashi E . The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway. Autophagy. 2016; 12(8):1406-8. PMC: 4968221. DOI: 10.1080/15548627.2016.1189070. View

12.

Chio A, Moglia C, Canosa A, Manera U, Grassano M, Vasta R . Exploring the phenotype of Italian patients with ALS with intermediate polyQ repeats. J Neurol Neurosurg Psychiatry. 2022; . PMC: 9606535. DOI: 10.1136/jnnp-2022-329376. View

13.

Li P, Moulick R, Feng H, Sun X, Arbez N, Jin J . RNA Toxicity and Perturbation of rRNA Processing in Spinocerebellar Ataxia Type 2. Mov Disord. 2021; 36(11):2519-2529. PMC: 8884117. DOI: 10.1002/mds.28729. View

14.

Watanabe R, Higashi S, Nonaka T, Kawakami I, Oshima K, Niizato K . Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions. Acta Neuropathol Commun. 2020; 8(1):176. PMC: 7594343. DOI: 10.1186/s40478-020-01055-9. View

15.

Rub U, Schols L, Paulson H, Auburger G, Kermer P, Jen J . Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol. 2013; 104:38-66. DOI: 10.1016/j.pneurobio.2013.01.001. View

16.

Figueroa K, Pulst S . Identification and expression of the gene for human ataxin-2-related protein on chromosome 16. Exp Neurol. 2004; 184(2):669-78. DOI: 10.1016/S0014-4886(03)00287-5. View

17.

Lee T, Li Y, Ingre C, Weber M, Grehl T, Gredal O . Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011; 20(9):1697-700. PMC: 3071667. DOI: 10.1093/hmg/ddr045. View

18.

Rubino E, Mancini C, Boschi S, Ferrero P, Ferrone M, Bianca S . ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol Aging. 2018; 73:231.e7-231.e9. DOI: 10.1016/j.neurobiolaging.2018.09.009. View

19.

Baumer D, East S, Tseu B, Zeman A, Hilton D, Talbot K . FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion. Acta Neuropathol. 2014; 128(4):597-604. DOI: 10.1007/s00401-014-1277-z. View

20.

Hart M, Gitler A . ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci. 2012; 32(27):9133-42. PMC: 3418890. DOI: 10.1523/JNEUROSCI.0996-12.2012. View